{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:26:24Z","timestamp":1778678784955,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deanship of Scientific Research (DSR) at King Abdulaziz University","award":["G: 236-140-1443"],"award-info":[{"award-number":["G: 236-140-1443"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Saudi Pharm. J."],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ulcerative colitis (UC) is a chronic inflammatory bowel disease resulting in mucosal inflammation and ulceration. Although tofacitinib, a Janus kinase inhibitor, is effective when administered systemically, its clinical use may be limited by systemic adverse effects. Thus, this study aimed to design and evaluate a colon\u2011targeted tofacitinib delivery system based on sodium alginate beads coated with Eudragit\u00ae S\u2011100 in a dextran sulfate sodium (DSS) induced colitis rat model. Tofacitinib was encapsulated within alginate beads and subsequently coated with Eudragit\u00ae S-100 for pH-dependent release. The beads were characterized for size, encapsulation efficiency, stability, and\n                    <jats:italic>in vitro<\/jats:italic>\n                    drug release. Therapeutic efficacy was evaluated in a 30-day DSS colitis model by histopathology, cytokine profiling, and drug concentrations in plasma and colon tissue. The colon-targeted beads exhibited minimal release under acidic gastric conditions and maximum release at the colonic pH.\n                    <jats:italic>In vivo<\/jats:italic>\n                    , the formulation significantly improved disease activity scores, preserved colonic architecture, and significantly reduced pro-inflammatory cytokines levels while increasing IL-10 levels. Colonic drug levels achieved with the formulated beads were substantially higher than those obtained with non\u2011formulated tofacitinib, accompanied by markedly reduced systemic exposure. As a conclusion, the colon-targeted tofacitinib delivery system may limit systemic exposure relative to conventional oral administration while maintaining therapeutic efficacy in experimental colitis. Nevertheless, comprehensive toxicological and long\u2011term safety studies are required before definitive conclusions regarding safety can be drawn.\n                  <\/jats:p>","DOI":"10.1007\/s44446-026-00076-0","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:44:23Z","timestamp":1775047463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Colon-targeted pH-responsive tofacitinib beads improve ulcerative colitis outcomes with lower systemic exposure"],"prefix":"10.1007","volume":"34","author":[{"given":"Ibrahim M.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Qadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama A. A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemah","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-4068","authenticated-orcid":false,"given":"Rania","family":"Magadmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Alharthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"3","key":"76_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1066896912470160","volume":"21","author":"B AbdullGaffar","year":"2013","unstructured":"AbdullGaffar B, Hotait H, Gopal P, Al-Awadhi S, Bamakhrama K, ElFaki B (2013) The prevalence and importance of crypt apoptosis, focal active cryptitis, and neutrophilic infiltrate of the lamina propria in colorectal adenomas. Int J Surg Pathol 21(3):247\u2013256. https:\/\/doi.org\/10.1177\/1066896912470160","journal-title":"Int J Surg Pathol"},{"issue":"6","key":"76_CR2","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1021\/acs.biomac.3c00260","volume":"24","author":"V Andretto","year":"2023","unstructured":"Andretto V, Taurino G, Guerriero G, Guerin H, Lain\u00e9 E, Bianchi MG, Agusti G, Brian\u00e7on S, Bussolati O, Clayer-Montembault A, Lollo G (2023) Nanoemulsions embedded in alginate beads as bioadhesive nanocomposites for intestinal delivery of the anti-inflammatory drug tofacitinib. Biomacromol 24(6):2892\u20132907. https:\/\/doi.org\/10.1021\/acs.biomac.3c00260","journal-title":"Biomacromol"},{"key":"76_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-017-0175-2","volume":"14","author":"DT Beattie","year":"2017","unstructured":"Beattie DT, Pulido-Rios MT, Shen F, Ho M, Situ E, Tsuruda PR, Brassil P, Kleinschek M, Hegde S (2017) Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy. J Inflamm Lond 14:28. https:\/\/doi.org\/10.1186\/s12950-017-0175-2","journal-title":"J Inflamm Lond"},{"issue":"2","key":"76_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1053\/j.gastro.2015.10.050","volume":"150","author":"F Carbonnel","year":"2016","unstructured":"Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F (2016) Methotrexate is not superior to placebo for inducing steroid-free remission but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology 150(2):380\u2013388. https:\/\/doi.org\/10.1053\/j.gastro.2015.10.050","journal-title":"Gastroenterology"},{"issue":"1","key":"76_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/0471142735.im1525s104","volume":"104","author":"B Chassaing","year":"2014","unstructured":"Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M (2014) Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol 104(1):15\u201325. https:\/\/doi.org\/10.1002\/0471142735.im1525s104","journal-title":"Curr Protoc Immunol"},{"issue":"4","key":"76_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2478\/v10007-012-0034-x","volume":"62","author":"A Chawla","year":"2012","unstructured":"Chawla A, Sharma P, Pawar P (2012) Eudragit S-100 coated sodium alginate microspheres of naproxen sodium: formulation, optimization and in vitro evaluation. Acta Pharm 62(4):529\u2013545. https:\/\/doi.org\/10.2478\/v10007-012-0034-x","journal-title":"Acta Pharm"},{"issue":"6","key":"76_CR7","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-877","volume":"10","author":"LJ Cui","year":"2022","unstructured":"Cui LJ, Yuan W, Chen FY, Wang YX, Li QM, Lin C, Miao XP (2022) Pectic polysaccharides ameliorate the pathology of ulcerative colitis in mice by reducing pyroptosis. Ann Transl Med 10(6):347. https:\/\/doi.org\/10.21037\/atm-22-877","journal-title":"Ann Transl Med"},{"issue":"3\u20132010","key":"76_CR8","first-page":"196","volume":"1","author":"NKD Devi","year":"2010","unstructured":"Devi NKD, Chandana M, Sindhura A, Ratnavali G, Kavitha R (2010) Comparative evaluation of alginate beads prepared by ionotropic gelation technique. Pharmacophore 1(3\u20132010):196\u2013213","journal-title":"Pharmacophore"},{"issue":"33","key":"76_CR9","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.3748\/wjg.v23.i33.6016","volume":"23","author":"DD Eichele","year":"2017","unstructured":"Eichele DD, Kharbanda KK (2017) Dextran sodium sulfate colitis murine model: an indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J Gastroenterol 23(33):6016. https:\/\/doi.org\/10.3748\/wjg.v23.i33.6016","journal-title":"World J Gastroenterol"},{"key":"76_CR10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2147\/DDDT.S101900","volume":"10","author":"KM El-Say","year":"2016","unstructured":"El-Say KM (2016) Maximizing the encapsulation efficiency and the bioavailability of controlled-release cetirizine microspheres using Draper-Lin small composite design. Drug des Dev Ther 10:825\u2013839. https:\/\/doi.org\/10.2147\/DDDT.S101900","journal-title":"Drug des Dev Ther"},{"issue":"3","key":"76_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/ecco-jcc\/jjaa209","volume":"15","author":"K Gerlach","year":"2021","unstructured":"Gerlach K, Lechner K, Popp V, Offensperger L, Zundler S, Wiendl M, Becker E, Atreya R, Rath T, Neurath MF, Weigman B (2021) The JAK1\/3 inhibitor to tofacitinib suppresses T cell homing and activation in chronic intestinal inflammation. J Crohns Colitis 15(3):465\u2013479. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa209","journal-title":"J Crohns Colitis"},{"issue":"7","key":"76_CR12","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.2174\/13816128113199990417","volume":"20","author":"K Gyires","year":"2014","unstructured":"Gyires K, Viktoria Toth E, Zoltan Zadori S (2014) Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities. Curr Pharm des 20(7):1063\u20131081. https:\/\/doi.org\/10.2174\/13816128113199990417","journal-title":"Curr Pharm des"},{"issue":"6","key":"76_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/00130832-200212000-00004","volume":"2","author":"SR Hofmann","year":"2002","unstructured":"Hofmann SR, Ettinger R, Zhou YJ, Gadina M, Lipsky P, Siegel R, Candotti F, O\u2019Shea JJ (2002) Cytokines and their role in lymphoid development, differentiation and homeostasis. Curr Opin Allergy Clin Immunol 2(6):495\u2013506. https:\/\/doi.org\/10.1097\/00130832-200212000-00004","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"76_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","volume":"15","author":"S Honap","year":"2024","unstructured":"Honap S, Agorogianni A, Colwill MJ, Mehta SK, Donovan F, Pollok R, Poullis A, Patel K (2024) JAK inhibitors for inflammatory bowel disease: recent advances. Frontline Gastroenterol 15(1):59\u201369. https:\/\/doi.org\/10.1136\/flgastro-2023-102400","journal-title":"Frontline Gastroenterol"},{"key":"76_CR15","doi-asserted-by":"publisher","unstructured":"Jeruc J (2022) Histomorphological diagnosis of ulcerative colitis and associated conditions. In ulcerative colitis-etiology, diagnosis, diet, special populations, and the role of interventional endoscopy. IntechOpen. https:\/\/doi.org\/10.5772\/intechopen.101234","DOI":"10.5772\/intechopen.101234"},{"key":"76_CR16","doi-asserted-by":"publisher","unstructured":"Kaur A, Goggolidou (2020) Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies. J Inflamm 17:1\u20138. https:\/\/doi.org\/10.1186\/s12950-020-00246-4","DOI":"10.1186\/s12950-020-00246-4"},{"issue":"1","key":"76_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T (2020) Ulcerative colitis. Nat Rev Dis Primers 6(1):74. https:\/\/doi.org\/10.1038\/s41572-020-0205-x","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"76_CR18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2174\/1567201817666200810110226","volume":"17","author":"D Kothale","year":"2020","unstructured":"Kothale D, Verma U, Dewangan N, Jana P, Jain A, Jain D (2020) Alginate as promising natural polymer for pharmaceutical, food, and biomedical applications. Curr Drug Deliv 17(9):755\u2013775. https:\/\/doi.org\/10.2174\/1567201817666200810110226","journal-title":"Curr Drug Deliv"},{"issue":"1","key":"76_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84761-1","volume":"11","author":"J Kwon","year":"2021","unstructured":"Kwon J, Lee C, Heo S, Kim B, Hyun CK (2021) DSS-induced colitis is associated with adipose tissue dysfunction and disrupted hepatic lipid metabolism leading to hepatosteatosis and dyslipidemia in mice. Sci Rep 11(1):5283. https:\/\/doi.org\/10.1038\/s41598-021-84761-1","journal-title":"Sci Rep"},{"key":"76_CR20","doi-asserted-by":"publisher","unstructured":"Kyatham RD, Bathula R, Sattu H (2024) Novel method development and validation of tofacitinib in bulk and pharmaceutical dosage form by RP-HPLC. PREPRINT (Version 1) available at research square https:\/\/doi.org\/10.21203\/rs.3.rs-5682411\/v1","DOI":"10.21203\/rs.3.rs-5682411\/v1"},{"issue":"1","key":"76_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/019262339902700124","volume":"27","author":"MW Leach","year":"1999","unstructured":"Leach MW, Davidson NJ, Fort MM, Powrie F, Rennick DM (1999) The role of IL-10 in inflammatory bowel disease: \u201cof mice and men.\u201d Toxicol Pathol 27(1):123\u2013133. https:\/\/doi.org\/10.1177\/019262339902700124","journal-title":"Toxicol Pathol"},{"issue":"7","key":"76_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11070318","volume":"11","author":"JS Lee","year":"2019","unstructured":"Lee JS, Kim SH (2019) Dose-dependent pharmacokinetics of tofacitinib in rats: influence of hepatic and intestinal first-pass metabolism. Pharmaceutics 11(7):318. https:\/\/doi.org\/10.3390\/pharmaceutics11070318","journal-title":"Pharmaceutics"},{"issue":"1","key":"76_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12010068","volume":"12","author":"SH Lee","year":"2020","unstructured":"Lee SH, Bajracharya R, Min JY, Han JW, Park BJ, Han HK (2020) Strategic approaches for colon targeted drug delivery: an overview of recent advancements. Pharmaceutics 12(1):68. https:\/\/doi.org\/10.3390\/pharmaceutics12010068","journal-title":"Pharmaceutics"},{"issue":"5","key":"76_CR24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3748\/wjg.v10.i5.620","volume":"10","author":"MC Li","year":"2004","unstructured":"Li MC, He SH (2004) IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 10(5):620\u2013625. https:\/\/doi.org\/10.3748\/wjg.v10.i5.620","journal-title":"World J Gastroenterol"},{"issue":"3","key":"76_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/gels9030187","volume":"9","author":"RT Malatani","year":"2023","unstructured":"Malatani RT, Bilal S, Mahmood A, Sarfraz RM, Zafar N, Ijaz H, Rehman U, Akbar S, Alkhalidi HM, Gad HA (2023) Development of tofacitinib loaded pH-responsive chitosan\/mucin based hydrogel microparticles: in-vitro characterization and toxicological screening. Gels 9(3):187. https:\/\/doi.org\/10.3390\/gels9030187","journal-title":"Gels"},{"issue":"4","key":"76_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1590\/S1984-82502010000400021","volume":"46","author":"S Mandal","year":"2010","unstructured":"Mandal S, Kumar SS, Krishnamoorthy B, Basu SK (2010) Development and evaluation of calcium alginate beads prepared by sequential and simultaneous methods. Braz J Pharm Sci 46(4):785\u2013793. https:\/\/doi.org\/10.1590\/S1984-82502010000400021","journal-title":"Braz J Pharm Sci"},{"issue":"2","key":"76_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/00914037.2025.2521406","volume":"75","author":"S Manna","year":"2025","unstructured":"Manna S, Nath NC, Sarkar P, Karmakar S, Gupta P, Jana S, Nandi G, Sen O (2025) Alginate-based target specific bioadhesive drug delivery systems: a review. Int J Polym Mater Polym Biomater 75(2):212\u2013238. https:\/\/doi.org\/10.1080\/00914037.2025.2521406","journal-title":"Int J Polym Mater Polym Biomater"},{"key":"76_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/2058739219843405","volume":"17","author":"D Meng","year":"2019","unstructured":"Meng D, Liang L, Guo X (2019) Serum IL-10 in inflammatory bowel disease: a meta-analysis. Eur J Inflamm 17:2058739219843405. https:\/\/doi.org\/10.1177\/2058739219843405","journal-title":"Eur J Inflamm"},{"issue":"4","key":"76_CR29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1365-3083.2005.01571.x","volume":"61","author":"A Mirshafiey","year":"2005","unstructured":"Mirshafiey A, Khodadadi A, Rehm BH, Khorramizadeh MR, Eslami MB, Razavi A, Saadat F (2005) Sodium alginate as a novel therapeutic option in experimental colitis. Scand J Immunol 61(4):316\u2013321. https:\/\/doi.org\/10.1111\/j.1365-3083.2005.01571.x","journal-title":"Scand J Immunol"},{"issue":"3","key":"76_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.22034\/iji.2011.17024","volume":"8","author":"M Mohammadi","year":"2011","unstructured":"Mohammadi M, Hayatbakhsh MM, Zahedi MJ, Jalalpour MR, Pakgohar A (2011) Serum interleukin-23 levels in patients with ulcerative colitis. Iran J Immunol 8(3):183\u2013188. https:\/\/doi.org\/10.22034\/iji.2011.17024","journal-title":"Iran J Immunol"},{"key":"76_CR31","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ijbiomac.2015.11.092","volume":"86","author":"S Mutalik","year":"2016","unstructured":"Mutalik S, Suthar NA, Managuli RS, Shetty PK, Avadhani K, Kalthur G, Kulkarni RV, Thomas R (2016) Development and performance evaluation of novel nanoparticles of a grafted copolymer loaded with curcumin. Int J Biol Macromol 86:709\u2013720. https:\/\/doi.org\/10.1016\/j.ijbiomac.2015.11.092","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"76_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","volume":"14","author":"MF Neurath","year":"2014","unstructured":"Neurath MF (2014) Cytokines in inflammatory bowel disease. Nat Rev Immunol 14(5):329\u2013342. https:\/\/doi.org\/10.1038\/nri3661","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"76_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/pharmaceutics15020587","volume":"15","author":"A Nikam","year":"2023","unstructured":"Nikam A, Sahoo PR, Musale S, Pagar RR, Paiva-Santos AC, Giram PS (2023) A systematic overview of Eudragit\u00ae based copolymer for smart healthcare. Pharmaceutics 15(2):587. https:\/\/doi.org\/10.3390\/pharmaceutics15020587","journal-title":"Pharmaceutics"},{"issue":"4","key":"76_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.15430\/JCP.2015.20.4.260","volume":"20","author":"YH Park","year":"2015","unstructured":"Park YH, Kim N, Shim YK, Choi YJ, Nam RH, Choi YJ, Ham MH, Suh JH, Lee SM, Lee CM, Yoon H (2015) Adequate dextran sodium sulfate-induced colitis model in mice and effective outcome measurement method. J Cancer Prev 20(4):260\u2013267. https:\/\/doi.org\/10.15430\/JCP.2015.20.4.260","journal-title":"J Cancer Prev"},{"issue":"2","key":"76_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.5001\/omj.2010.24","volume":"25","author":"AK Philip","year":"2010","unstructured":"Philip AK, Philip B (2010) Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J 25(2):70\u201378. https:\/\/doi.org\/10.5001\/omj.2010.24","journal-title":"Oman Med J"},{"issue":"12","key":"76_CR36","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/jgh.16811","volume":"39","author":"CA Rubio","year":"2024","unstructured":"Rubio CA, Lang-Schwarz C, Vieth M (2024) Architectural crypt distortions in ulcerative colitis: time for reappraisal. J Gastroenterol Hepatol 39(12):2479\u20132486. https:\/\/doi.org\/10.1111\/jgh.16811","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"76_CR37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","volume":"17","author":"A Salas","year":"2020","unstructured":"Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, Vetrano S, Vande Casteele N (2020) JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 17(6):323\u2013337. https:\/\/doi.org\/10.1038\/s41575-020-0273-0","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"18","key":"76_CR38","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376(18):1723\u20131736. https:\/\/doi.org\/10.1056\/NEJMoa1606910","journal-title":"N Engl J Med"},{"issue":"7","key":"76_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3109\/02652040802500622","volume":"26","author":"T Suksamran","year":"2009","unstructured":"Suksamran T, Opanasopit P, Rojanarata T, Ngawhirunpat T, Ruktanonchai U, Supaphol P (2009) Biodegradable alginate microparticles developed by electrohydrodynamic spraying techniques for oral delivery of protein. J Microencapsul 26(7):563\u2013570. https:\/\/doi.org\/10.3109\/02652040802500622","journal-title":"J Microencapsul"},{"issue":"2","key":"76_CR40","first-page":"659","volume":"38","author":"B Taka\u010d","year":"2014","unstructured":"Taka\u010d B, Mihaljevi\u0107 S, \u0160tefani\u0107 M, Glava\u0161-Obrovac L, Kibel A, Samard\u017eija M (2014) Importance of interleukin 6 in pathogenesis of inflammatory bowel disease. Coll Antropol 38(2):659\u2013664","journal-title":"Coll Antropol"},{"issue":"1","key":"76_CR41","first-page":"1","volume":"5","author":"RK Tiwari","year":"2013","unstructured":"Tiwari RK, Singh L, Sharma V (2013) Alginate micro-beads in novel drug delivery system: an overview. Int J Pharm Technol 5(1):1\u201313","journal-title":"Int J Pharm Technol"},{"issue":"11","key":"76_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14113690","volume":"14","author":"V Villanacci","year":"2025","unstructured":"Villanacci V, Maconi G, Laschi L, Bassotti G (2025) Diagnosing ulcerative colitis: should we go beyond the surface? J Clin Med 14(11):3690. https:\/\/doi.org\/10.3390\/jcm14113690","journal-title":"J Clin Med"},{"issue":"7","key":"76_CR43","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/ibd\/izy131","volume":"25","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C (2018) Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis 25(7):1130\u20131138. https:\/\/doi.org\/10.1093\/ibd\/izy131","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"76_CR44","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.3390\/pharmaceutics14112385","volume":"14","author":"V Yadav","year":"2022","unstructured":"Yadav V, House A, Matiz S, McCoubrey LE, Bettano KA, Bhave L, Wang M","journal-title":"Pharmaceutics"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-026-00076-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44446-026-00076-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-026-00076-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:38:25Z","timestamp":1778675905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44446-026-00076-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["76"],"URL":"https:\/\/doi.org\/10.1007\/s44446-026-00076-0","relation":{},"ISSN":["1319-0164","2213-7475"],"issn-type":[{"value":"1319-0164","type":"print"},{"value":"2213-7475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All in vivo experimental procedures were reviewed and approved by the Research Ethics Committee of the Faculty of Pharmacy, King Abdulaziz University (Approval No. PH\u20111444\u201121, dated 6 December 2022). All experiments were conducted in accordance with the institutional guidelines for the care and use of laboratory animals and adhered to the regulations of the National Committee of Bioethics (NCBE), Saudi Arabia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}],"article-number":"18"}}